Segura J, Borja L, Bakke O M
Arch Int Pharmacodyn Ther. 1976 Sep;223(1):88-95.
The plasma concentration of sulpiride was measured in the rat and in the dog after oral and i.v. administration of the drug. In the rat only traces (less than 1 mug/ml) of sulpiride were detected in plasma after an oral dose of 100 mg/kg. The peak concentrations in 3 dogs given 25, 50 or 100 mg/kg orally were 6.1, 15.6 and 23.9 mug/ml, respectively. The pharmacokinetic data after i.v. injection were compared to earlier observations with the related orthopramide compound, metoclopramide. The half-life of sulpiride in dog plasma (1.6 -- 3.4 hr) is longer than that of metoclopramide, but in the rat there is little difference between the two compounds. Both of the compounds have large total apparent volumes of distribution (1-2 1/kg) in the two species. The marked species difference in the systemic bioavailability of oral sulpiride should be taken into account when the orthopramide drugs are evaluated in pharmacological tests.
在大鼠和犬口服及静脉注射舒必利后,测定了其血浆浓度。给大鼠口服100mg/kg剂量后,血浆中仅检测到痕量(小于1μg/ml)的舒必利。三只分别口服25、50或100mg/kg舒必利的犬,其血药峰浓度分别为6.1、15.6和23.9μg/ml。将静脉注射后的药代动力学数据与早期对相关的邻苯甲酰胺类化合物甲氧氯普胺的观察结果进行了比较。舒必利在犬血浆中的半衰期(1.6 - 3.4小时)比甲氧氯普胺长,但在大鼠中,这两种化合物之间差异不大。两种化合物在这两个物种中的总表观分布容积都很大(1 - 2l/kg)。在对邻苯甲酰胺类药物进行药理试验评估时,应考虑口服舒必利全身生物利用度存在的显著种属差异。